{
    "nctId": "NCT02909751",
    "briefTitle": "Tocotrienol in Combination With Neoadjuvant Chemotherapy for Women With Breast Cancer",
    "officialTitle": "Tocotrienol in Combination With Neoadjuvant Chemotherapy for Women With Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 80,
    "primaryOutcomeMeasure": "Pathological complete response",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Women with histologically verified breast cancer (adenocarcinoma)\n* Age \u2265 18 years.\n* Neoadjuvant treatment indicated according to departmental guidelines\n* PS 0-2 and suited for surgery.\n* Normal heart function, LVEF \u2265 50% by MUGA/ECHO in patients receiving neoadjuvant trastuzumab\n* Normal bone marrow function: Hemoglobin \u2265 6 mmol/l; ANC \u2265 1.5x10\\^9/l; Thrombocytes \u2265 100x10\\^9/l.\n* Normal liver function: Bilirubin \u2264 1.5 x upper level of normal, ALAT \u2264 2.5 x upper level of normal, BASP \u2264 2.5 x upper level of normal.\n* Normal kidney function: Creatinine \u2264 upper level of normal. In case of increased creatinine, measured/calculated GFR must be \u2265 50 ml/min.\n* Fertile women must present a negative pregnancy test and use a safe contraceptive during and 3 months after the treatment. Intrauterine device without hormone is considered safe.\n* Written and orally informed consent\n\nExclusion Criteria:\n\n* Bilateral breast cancer or suspected dissemination. Verified by bilateral mammography, bone scintigraphy, chest and abdomen CT, and PET-CT.\n* Pregnant and breastfeeding women\n* Mental or social conditions that will prevent treatment or follow-up\n* Other simultaneous experimental treatment\n* Immunosuppressive treatment (other than prednisolone during neoadjuvant chemotherapy)\n* Vitamin or nutritional supplements (other than multivitamin tablet and calcium tablet with vitamin D)\n* Active or latent viral/bacterial infection\n* Rheumatoid arthritis or other autoimmune disease\n* Other malignant disease within the past 5 years excl. non-melanoma cancer of the skin and carcinoma in situ cervicis uteri.\n* Previous treatment with docetaxel, paclitaxel, epirubicin, cyclophosphamide, trastuzumab, pertuzumab or tocotrienol\n* Hypersensitivity to any of the active or auxiliary substances",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}